Symbols / FBIO

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan Mon, 23 Feb 2026 13
• FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy - Stocktwits Mon, 23 Feb 2026 17
• Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap - Seeking Alpha Fri, 20 Feb 2026 02
• Gossamer Bio stock tumbles 80% on trial miss - Investing.com Mon, 23 Feb 2026 13
• Gossamer Bio fails phase 3 pulmonary arterial hypertension trial - Fierce Biotech Mon, 23 Feb 2026 14
• FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biotech | FBIO Stock News - GuruFocus Mon, 23 Feb 2026 16
• Gossamer Bio shares plummet as lung disease drug fails late-stage trial - Reuters Mon, 23 Feb 2026 13
• Upstream Bio’s stock drops 47% on verekitug Phase II asthma data - Clinical Trials Arena hu, 12 Feb 2026 08
• Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability - Yahoo Finance Sun, 18 Jan 2026 08
• Why This Biotech Crashed Almost 50% On Its Asthma Win - Investor's Business Daily Wed, 11 Feb 2026 08
• Gossamer Bio stock tumbles again premarket as Phase 3 PAH miss rewrites the story - TechStock² ue, 24 Feb 2026 10
• Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower - simplywall.st hu, 05 Feb 2026 08
• Fortress Biotech (Nasdaq: FBIO): FDA accepts Class 1 resubmission, CUTX-101 PDUFA Jan. 14, 2026 - Stock Titan Mon, 15 Dec 2025 08
• Barclays cuts Gossamer Bio stock rating on trial results - Investing.com South Africa ue, 24 Feb 2026 16
• What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance Fri, 30 Jan 2026 08

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 8-K2026-02-23 View
• 8-K2026-01-13 View
• 42026-01-06 View
• 42026-01-05 View
• 42026-01-05 View
• 42026-01-05 View
• 42026-01-05 View
• 42026-01-05 View
• 42026-01-05 View
• 8-K2025-12-15 View
• 8-K2025-12-15 View
• 8-K2025-11-17 View
• 10-Q2025-11-14 View
• 8-K2025-11-14 View
• 42025-10-02 View